Brief: Lee's Pharmaceutical Says NDA Of Socazolimab Submitted, Accepted By China's NMPA
27/10/2021 16:22
Oct 27 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* NDA OF SOCAZOLIMAB FOR TREATMENT OF RECURRENT OR
METASTATIC
CERVICAL CANCER SUBMITTED AND ACCEPTED BY CHINA'S NMPA
Source text for Eikon: ID:
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals